Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis
Hongchao Li,1 Wei He,2 Hongbo Lin,3 Angying Du,4 Xue Zhang,5 Han Yang,5 Shuli Qu5 1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, People's Republic of China; 2Fertility and Reproductive Medicine Centre, The Southwest Hospital of AMU, Chongqing...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2024-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_dc33a4cf7ed14adf9d05cbc51afd2e11 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Li H |e author |
| 700 | 1 | 0 | |a He W |e author |
| 700 | 1 | 0 | |a Lin H |e author |
| 700 | 1 | 0 | |a Du A |e author |
| 700 | 1 | 0 | |a Zhang X |e author |
| 700 | 1 | 0 | |a Yang H |e author |
| 700 | 1 | 0 | |a Qu S |e author |
| 245 | 0 | 0 | |a Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis |
| 260 | |b Dove Medical Press, |c 2024-05-01T00:00:00Z. | ||
| 500 | |a 1179-1594 | ||
| 520 | |a Hongchao Li,1 Wei He,2 Hongbo Lin,3 Angying Du,4 Xue Zhang,5 Han Yang,5 Shuli Qu5 1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, People's Republic of China; 2Fertility and Reproductive Medicine Centre, The Southwest Hospital of AMU, Chongqing, 400038, People's Republic of China; 3Department of Reproductive Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, People's Republic of China; 4Merck Serono, an Affiliate of Merck KGaA Darmstadt Germany, Beijing, 100016, People's Republic of China; 5Real-World Solutions, IQVIA, Shanghai, 200041, People's Republic of ChinaCorrespondence: Shuli Qu, Real-World Solutions, IQVIA, 1359 Yaolong Road, Shanghai, People's Republic of China, Email shuli.qu1@iqvia.comBackground: To compare the cost-effectiveness of originator (reference) recombinant human follicle stimulating hormone alfa (rhFSH-α) (follitropin alfa, GONAL-f) and its biosimilar (rhFSH, JinSaiHeng) in assisted reproductive technology (ART) from a Chinese patient perspective.Methods: A decision tree model was developed to simulate the treatment pathway of infertile women undergoing ART using GONAL-f or JinSaiHeng. Published clinical and cost data were used to evaluate the cost-effectiveness of the rhFSH-α. The cumulative live birth rate (CLBR), direct medical costs and costs per cumulative live birth were estimated via an analytic decision-tree model.Results: CLBR of GONAL-f was higher than JinSaiHeng preparation (88.3% vs 84.4%), while the cost per cumulative live birth was lower (51,475 vs 52,095 CNY).Conclusion: The originator rhFSH-α was associated with higher CLBR and lower cost per cumulative live birth, with incremental cost per additional live birth of 38,096 CNY (Chinese Yuan).Keywords: recombinant human follicle stimulating hormone, controlled ovarian stimulation, assisted reproductive technology, cost-effectiveness analysis | ||
| 546 | |a EN | ||
| 690 | |a recombinant human follicle stimulating hormone | ||
| 690 | |a controlled ovarian stimulation | ||
| 690 | |a assisted reproductive technology | ||
| 690 | |a cost-effectiveness analysis. | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Risk Management and Healthcare Policy, Vol Volume 17, Pp 1387-1394 (2024) | |
| 787 | 0 | |n https://www.dovepress.com/recombinant-human-follicle-stimulating-hormone-in-controlled-ovarian-h-peer-reviewed-fulltext-article-RMHP | |
| 787 | 0 | |n https://doaj.org/toc/1179-1594 | |
| 856 | 4 | 1 | |u https://doaj.org/article/dc33a4cf7ed14adf9d05cbc51afd2e11 |z Connect to this object online. |